### Highlights of This Issue 6953

#### SPECIAL FEATURES

**CCR Translations**

6955  
MAGE: The Spell Is Broken  
Katayoun Rezvani  
*See article p. 7058*

**CCR Drug Updates**

6958  
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma  
Evan J. Lipson and Charles G. Drake

**Molecular Pathways**

6963  
Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells  
Nicola Giuliani and Irma Airoldi

**Perspective**

6971  
DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies  
Graham A. Colditz and John Crowley

**Reviews**

6973  
DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target  
Shadia Jalal, Jennifer N. Earley, and John J. Turchi

6985  
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives  
Jessica Godin-Ethier, Laila-Aicha Hanafi, Ciriaco A. Piccirillo, and Réjean Lapointe

---

**HUMAN CANCER BIOLOGY**

6992  
Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I  
Trisha R. Sippel, Jason White, Kamalika Nag, Vadim Tsvankin, Marci Klassen, B.K. Kleinschmidt-DeMasters, and Allen Waziri

7003  
Novel Chromosomal Rearrangements and Break Points at the (6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome  

7015  
Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma  
David Z. Chang, Ying Ma, Baosun Ji, Huamin Wang, Defeng Deng, Yan Liu, James L. Abbruzzese, Yongjun Liu, Craig D. Logsdon, and Patrick Hwu

7024  
Two Distinct Routes to Oral Cancer Differing in Genome Instability and Risk for Cervical Node Metastasis  

7035  
Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium  
Hannah Barrow, Xiuli Guo, Hans H. Wandall, Johannes W. Pedersen, Bo Fu, Qicheng Zhao, Chen Chen, Jonathan M. Rhodes, and Lu-Gang Yu
CANCER THERAPY: PRECLINICAL

7047  Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
Yuhuan Li, Li-Xin Wang, Puiyi Pang, Zhihua Cui, Sandra Aung, Daniel Haley, Bernard A. Fox, Walter J. Urba, and Hong-Ming Hu

7058  Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
Conrad R. Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Andrea Sheehan, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Heslop, and Catherine M. Bollard
See commentary p. 6955

IMAGING, DIAGNOSIS, PROGNOSIS

7139  Genetic Variation in Inflammatory Pathways Is Related to Colorectal Cancer Survival
Anna E. Coghill, Polly A. Newcomb, Elizabeth M. Poole, Carolyn M. Hutter, Karen W. Makar, Dave Duggan, John D. Potter, and Cornelia M. Ulrich

CANCER THERAPY: CLINICAL

7156  Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau, Brooke Esteves, Chunhong He, Meizhong Xu, Jinfeng Zhao, Wenqing Yao, Robert C. Newton, and Peggy A. Scherle

7164  A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Mabsa Mohibshah, Kwong-Yok Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole, Caroline Jochems, Jiacquin Jones, Theresa Ferrara, Christopher R. Heery, Philip M. Arlen, Seth M. Steinberg, Mary Pazdur, Myrna Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlim, and James L. Gulley

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu, Qian Wang, Gengjie Yang, Cindy Marando, Holly K. Kobish, Leslie M. Hall, Jordan S. Fridman, Elham Behshad, Richard Wynn, Yu Li, Jason Boer, Sharon Diamond, Chunhong He, Meizhong Xu, Jinfeng Zhao, Wenqing Yao, Robert C. Newton, and Peggy A. Scherle

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendrogial Brain Tumors: A Report from EORTC Study 26951
Martin J. van den Bent, Loneke A. Gravendeel, Thierry Gorlia, Johan M. Kros, Larèsa Lapre, Pieter Wesseling, Johannes L. Teepen, Ahmed Idbhai, Marc Sanson, Peter A.E. Sillevis Smitt, and Pim J. French

Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells

Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies

Synergistic Activity of Fenretinide and the Bel-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma
Hua Fang, Theresa M. Harned, Ondrej Kalous, Vanessa Maldonado, Yesa A. DeClerck, and C. Patrick Reynolds

Reduced miR-128 in Breast Tumor–Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCG2
Yinghua Zhu, Fengyan Yu, Yu Jiao, Juan Feng, Wei Tang, Herui Yao, Chang Gong, Jiaying Chen, Fengxi Su, Yan Zhang, and Erwei Song

Novel Phosphoinositide 3-kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo
Kwang-Yu Chang, Shan-Yin Tsai, Ching-Ming Wu, Chia-Jui Yen, Bin-Fay Chuang, and Jang-Yang Chang
GLIIR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy

Guru Sonpavde, Timothy C. Thompson, Rajul K. Jain, Gustavo E. Ayala, Shini Kurosaka, Kohbi Edamura, Ken-Ichi Tabata, Chengzhen Ren, Alexei A. Goltsov, Martha P. Mims, Teresa G. Hayes, Michael M. Ittmann, Thomas M. Wheeler, Adrian Gee, Brian J. Miles, and Dov Kadmon

Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437

Monica M. Reinholz, Kathleen A. Kitzmann, Kathleen Tenner, David Hillman, Amylou C. Dueck, Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno-Aspitia, Vivek Roy, Betsy LaPlant, Jake B. Allred, Philip J. Stella, Wilma L. Lingle, and Edith A. Perez

Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer


ABOUT THE COVER

Human melanoma xenografts of UACC903 cells with activated BRAF mutation (V600E) were either untreated or treated with vehicle (DMSO) or the compounds riluzole, sorafenib, or riluzole with sorafenib. Upon termination of the experiment, the remaining tumors were excised and stained with activated caspase-3. This image is vehicle control. For details, see the article by Lee and colleagues on page 7080 of this issue.